Leukemia: A Review of Data from the ASH 2022 Meeting

Elias Jabbour, MD, an expert on leukemia

EP. 1: ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape

BySameem Abedin, MD,Elias Jabbour, MD,Harry Erba, MD, PhD,Anjali Advani, MD

February 14th 2023

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Anjali Advani, MD, an expert on leukemia

EP. 2: ASH 2022: Recent Advances in Chronic Myeloid Leukemia

BySameem Abedin, MD,Elias Jabbour, MD,Harry Erba, MD, PhD,Anjali Advani, MD

February 14th 2023

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Harry Erba, MD, PhD, an expert on leukemia

EP. 3: Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting

BySameem Abedin, MD,Elias Jabbour, MD,Harry Erba, MD, PhD,Anjali Advani, MD

February 14th 2023

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

Trending on OncLive

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors

mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC

Harold P. Freeman, MD, Pioneer of Patient Navigation and Cancer Disparities Research, Dies at 93